Teva wins FDA approval for monthly schizophrenia injection Weltruza
Teva has received FDA approval for once monthly injectable schizophrenia drug Weltruza. The announcement sent Teva shares gaining in premarket.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Medincell partner wins FDA approval for WELTRUZA
Medincell said its partner Teva announced U.S. FDA approval of WELTRUZA, an extended-release injectable suspension of olanzapine for adults with schizophrenia. Teva plans to make the treatment available in the United States in the coming weeks.